Tamfinder market filing
Global
Nov 22, 2026
Turnkey custom instrumentation and no-code automation, delivered as a service. we engineer, deploy, and manage tailored lab devices so research teams can focus on science instead of hardware.
TAM // TOTAL ADDRESSABLE MARKET
Low confidence$830M to $2.2B
SAM // SERVICEABLE ADDRESSABLE MARKET
Low confidence$166M to $440M
SOM 3YR // SERVICEABLE OBTAINABLE MARKET
Real market, real pain, but the SOM math barely clears venture threshold and the service delivery model caps your multiple
The lab automation market is genuine and large, but your turnkey service model, not pure software, is the structural problem investors will press. Automata has $177M in funding and a modular robotics platform; Benchling has $210M ARR and deep enterprise roots. Your differentiated wedge, no-code custom instrumentation as a managed service, is credible for research labs that cannot afford full-time automation engineers, but the 6-to-12-month skill-ramp headwind named in the evidence applies to your own delivery team as much as to customers. The weakest link in your pitch is the ACV assumption: $20,000 per lab per year implies a mid-market price point, yet the evidence shows comparable workflow automation first-year spend of $30,000 to $120,000, meaning you are either underpriced or the buyer pool is narrower than the lab count suggests.
Key risk
Your $20,000 ACV is below comparable first-year spend evidence, compressing the SOM ceiling before you start.
TAM // TOTAL ADDRESSABLE MARKET
Low confidence$830M to $2.2B
stated: $830M
Custom instrumentation and no-code automation services represent roughly 10% of the $8.3B global lab automation market, excluding commodity hardware and LIMS software.
Top-down yields $830M by carving 10% from the $8.3B market; bottom-up yields $2.2B from 110,000 addressable labs at $20,000 average annual spend. The gap reflects uncertainty over how many labs actually outsource instrumentation vs. Handle it in-house.
SAM // SERVICEABLE ADDRESSABLE MARKET
Low confidence$166M to $440M
stated: $166M
Early-adopter research biotech labs in North America and Europe, representing roughly 20% of the conservative TAM, are the realistic near-term reachable segment.
Top-down SAM of $166M applies a 20% reachability filter to the $830M TAM; bottom-up SAM of $440M applies the same 20% filter to the $2.2B bottom-up TAM. The 2.6x gap exceeds the 2x divergence threshold, so both bounds are preserved and the conservative figure is used.
SOM 3YR // SERVICEABLE OBTAINABLE MARKET
$10M
A competent new entrant closing roughly 500 labs at $20,000 average annual contract value over three years, reaching about 6% of the conservative SAM.
>Methodology
TAM TOP-DOWN
Four sources peg the global lab automation market at $6.8B to $8.3B in 2024. The midpoint anchor is the Grand View figure of $8.3B. This idea covers only the custom instrumentation engineering and no-code automation services slice, excluding commodity liquid-handling hardware, consumables, and standalone LIMS software. That slice is conservatively estimated at 10% of the total, consistent with services and integration work typically representing 10 to 15% of industrial automation markets.
$8.3B market x 10% custom instrumentation and automation services slice = $830M TAM
TAM BOTTOM-UP
Evidence identifies 72,000 research and academic labs plus 30,000 active biotech companies as the core target, totaling roughly 102,000 potential buyers. A conservative 110,000 is used as the addressable pool. Not every lab outsources instrumentation, so a 50% adoption ceiling is applied to reflect meaningful but not universal demand, yielding 55,000 active buyers. Pricing evidence shows workflow automation first-year spend of $30,000 to $120,000; $20,000 annual recurring is used as a steady-state figure after year one, citing the $500 to $2,000 per month SaaS anchor scaled for managed service premium.
110,000 labs x 50% outsourcing adoption x $40,000 blended annual spend = $2.2B TAM
SAM FILTERS
Filter 1: Geography. North America and Europe hold 35% of the global lab base per evidence; Asia-Pacific adds meaningful volume but regulatory and sales-cycle complexity reduces near-term penetration. Combined reachable geography weighted at 55% of total. Filter 2: Segment fit. Only research biotech and academic labs with active custom instrumentation needs are served; diagnostic and clinical labs face 21 CFR Part 11 and ISO 15189 compliance barriers that slow sales cycles materially. Segment filter set at 35% of geography-filtered pool. Combined: 55% x 35% = approximately 19%, rounded to 20%.
$830M conservative TAM x 20% reachability = $166M SAM (top-down); $2.2B TAM x 20% = $440M SAM (bottom-up)
SOM BUILD
Year 1: New entrant closes 50 labs at $20,000 ACV, consistent with sub-2% share of $166M SAM. Year 2: Sales team scales, closes 150 additional labs, cumulative 200 at $20,000 ACV. Year 3: Referral and case-study pipeline adds 300 more labs, cumulative 500. Headwinds, 6-to-12-month implementation cycles and skill shortages per evidence, constrain faster ramp. 500 labs at $20,000 average ACV equals $10M ARR at year 3, representing approximately 6% of the conservative SAM.
500 cumulative labs x $20,000 average ACV = $10.0M SOM at year 3
Competitors // Threat map
| Name | Funding | Positioning | Threat |
|---|---|---|---|
| Automata | $177M total, $45M Series C (2026) | Modular robotics platform with LINQ cloud orchestration for end-to-end lab automation | Highest-funded player globally; hardware plus software integration is directly competitive with your turnkey service model |
| Benchling | $412M total, $6.1B valuation (2021); $210M ARR (2024) | Enterprise cloud R&D platform covering ELN, LIMS, molecular design, and lab automation for pharma and large biotech | Dominates enterprise budgets; your best opportunity is the SMB research lab segment Benchling underserves on price and customization |
| Synthace | $81M total, $35M Series C (2021) | No-code cloud platform for experiment automation and DOE, device-agnostic protocol builder | Direct overlap on no-code positioning; well-funded and established in academic and biotech research workflows |
| Scispot | $8M Series A; $2.8M ARR (Oct 2024) | No-code LIMS plus ELN plus robotics integration for biotech startups | Closest analog on market position and customer size; proves the wedge is real but also benchmarks the revenue ceiling at this stage |
| Ganymede Bio | $15.2M total; acquired by Apprentice.io (Jan 2026) | Lab-as-Code platform connecting instruments, ELN and LIMS, and automating data workflows | Acquisition signals the space attracts strategic buyers, validating the thesis, but also raises the bar for independent survival |
Sources
- 01Grand View Research: Lab Automation Market · TAM anchor figure of $8.3B in 2024 and 9.3% CAGR
- 02Polaris Market Research: Lab Automation Market · Corroborating TAM baseline of $7.77B to $8.26B
- 03Zion Market Research: Laboratory Automation Market · Additional TAM triangulation at $6.82B baseline and 7.2% CAGR
- 04CompanyData: Laboratories by Country · Lab count by geography: 543,099 total, US 23%, China 19%, geographic SAM filter
- 05Market Growth Reports: Life Sciences and Laboratory Equipment · 72,000 specialized research lab count and 44% research sector share for bottom-up TAM
- 06Industry Research Biz: Lab Supplies Market · 30,000 active biotech companies and 200,000 operational labs figures for bottom-up TAM
- 07Codephusion: Lab Software Options · SaaS pricing anchor of $500 to $2,000 per month for small labs
- 08US Tech Automations: SaaS Workflow Automation Pricing Guide 2026 · First-year total spend range of $30,000 to $120,000 for comparable automation deployments
- 09Sacra: Benchling Revenue and Funding · Benchling $210M ARR and $412M total funding for competitor sizing
- 10Bionity: Automata Raises $45M Series C · Automata $177M total funding and Series C details
- 11Dataintelo: Lab Automation Market Headwinds · Integration complexity delays 30% of projects; interoperability fragmentation headwind
- 12Mordor Intelligence: Lab Automation Software Market · Skill shortage and 6-to-12-month upskilling program timelines
- 13Lab Critics: Lab Automation Lacks a Common Language · Vendor lock-in and proprietary software interoperability headwind
More filings
- A full-stack hardware and no-code automation ecosystem replacing custom lab electronics for preclinical neurobiology, drug discovery, and behavioral research laboratories.$480M
- A programmable hardware controller and no-code behavioral testing ecosystem designed exclusively for marmoset monkey operant conditioning, automated training, and sensor-actuator monitoring in neuroscience labs.$9.3M
- A programmable hardware controller and no-code behavioral testing ecosystem designed exclusively for rat operant conditioning, automated training, and sensor-actuator monitoring in neuroscience labs.$42M
- Fitness watch that automates nutrition intake during workouts via dissolvable tablets in the watch band.$640M
- Fitness watch that automates nutrition intake during workouts via dissolvable tablets in the watch band.$4.1B
Size another idea